

Bcl9L Antibody

Catalog # ASC11289

Product Information

Application	WB, ICC, E
Primary Accession	Q86UU0
Other Accession	NP_872363 , 32698936
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Calculated MW	157129
Concentration (mg/ml)	1 mg/mL
Conjugate	Unconjugated
Application Notes	Bcl9L antibody can be used for detection of Bcl9L by Western blot at 1 μ g/mL. Antibody can also be used for immunocytochemistry starting at 10 μ g/mL.

Additional Information

Gene ID	283149
Other Names	B-cell CLL/lymphoma 9-like protein, B-cell lymphoma 9-like protein, BCL9-like protein, Protein BCL9-2, BCL9L, DLNB11
Target/Specificity	BCL9L; Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist; this antibody will detect all four.
Reconstitution & Storage	Bcl9L antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Precautions	Bcl9L Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	BCL9L
Synonyms	DLNB11
Function	Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1 (By similarity).
Cellular Location	Nucleus

Tissue Location

Expressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level). Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck tumors and embryonal tumor.


Background

Bcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

References

- Katoh M and Katoh M. Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico. *Int. J. Mol. Med.* 2003; 12:643-9.
- Adachi S, Jigami T, Yasui T, et al. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. *Cancer Res.* 2004; 64:8496-501.
- Toya H, Oyama T, Ohwada S, et al. Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers. *Cancer Sci.* 2007; 98:484-90.
- Deka J, Wiedemann N, Anderle P, et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinoma. *Cancer Res.* 2010; 70:6619-28.

Images



Western blot analysis of Bcl9L in HeLa cell lysate with Bcl9L antibody at 1 μ g/mL in (A) the absence and (B) the presence of blocking peptide.



Immunocytochemistry of Bcl9L in HeLa cells with Bcl9L antibody at 10 μ g/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.